BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
BC Extra | Sep 6, 2017
Company News

Novartis names CMO Narasimhan to replace CEO Jimenez

On Monday, Novartis AG (NYSE:NVS; SIX:NOVN) said CMO Vasant Narasimhan will replace CEO Joseph Jimenez, effective Feb. 1, 2018. Jimenez, who is retiring, led the pharma through multiple patent expirations, business integrations and reorganizations. Jimenez...
BioCentury | Jul 21, 2017
Finance

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc. , the $50.5 million round announced July 20 is...
BC Week In Review | Dec 30, 2016
Company News

Ziarco, Novartis deal

Novartis will acquire Ziarco for undisclosed financial terms. The deal gives the pharma ZPL-389 , an oral histamine H4 receptor ( HRH4 ; H4) antagonist. Ziarco previously said ZPL-389 missed the primary endpoint but significantly reduced Eczema...
BC Extra | Dec 16, 2016
Company News

Novartis gets eczema candidate in Ziarco takeout

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring Ziarco Group Ltd. (Canterbury, U.K.). The deal gives the pharma ZPL-389 , an oral histamine H4 receptor ( HRH4 ; H4) antagonist that has completed a Phase IIa trial to treat...
BC Week In Review | May 23, 2016
Clinical News

ZPL-389: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 98 patients with moderate to severe atopic dermatitis showed that once-daily 30 mg oral ZPL-389 missed the primary endpoint of improving NRS for pruritus from...
BC Extra | May 17, 2016
Clinical News

Ziarco planning atopic dermatitis Phase IIb

Ziarco Group Ltd. (Canterbury, U.K.) said ZPL-389 missed the primary endpoint of pruritus as measured on a numerical rating scale vs. placebo in a 98-patient Phase IIa study to treat moderate to severe atopic dermatitis....
BioCentury | May 16, 2016
Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
BC Week In Review | Feb 8, 2016
Clinical News

ZPL-389: Phase IIa started

Ziarco began a double-blind, placebo-controlled, international Phase IIa trial to evaluate 30 mg oral ZPL-389 once daily for 12 weeks in about 120 patients with moderate to severe psoriasis. Ziarco has exclusive, worldwide rights to...
BC Week In Review | Jul 13, 2015
Clinical News

ZPL-398: Phase IIa started

Ziarco began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 30 mg ZPL-398 once daily for 8 weeks in 90 patients with moderate to severe atopic dermatitis. Ziarco Group Ltd. , Canterbury, U.K.   Product:...
Items per page:
1 - 10 of 21
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
BC Extra | Sep 6, 2017
Company News

Novartis names CMO Narasimhan to replace CEO Jimenez

On Monday, Novartis AG (NYSE:NVS; SIX:NOVN) said CMO Vasant Narasimhan will replace CEO Joseph Jimenez, effective Feb. 1, 2018. Jimenez, who is retiring, led the pharma through multiple patent expirations, business integrations and reorganizations. Jimenez...
BioCentury | Jul 21, 2017
Finance

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc. , the $50.5 million round announced July 20 is...
BC Week In Review | Dec 30, 2016
Company News

Ziarco, Novartis deal

Novartis will acquire Ziarco for undisclosed financial terms. The deal gives the pharma ZPL-389 , an oral histamine H4 receptor ( HRH4 ; H4) antagonist. Ziarco previously said ZPL-389 missed the primary endpoint but significantly reduced Eczema...
BC Extra | Dec 16, 2016
Company News

Novartis gets eczema candidate in Ziarco takeout

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring Ziarco Group Ltd. (Canterbury, U.K.). The deal gives the pharma ZPL-389 , an oral histamine H4 receptor ( HRH4 ; H4) antagonist that has completed a Phase IIa trial to treat...
BC Week In Review | May 23, 2016
Clinical News

ZPL-389: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 98 patients with moderate to severe atopic dermatitis showed that once-daily 30 mg oral ZPL-389 missed the primary endpoint of improving NRS for pruritus from...
BC Extra | May 17, 2016
Clinical News

Ziarco planning atopic dermatitis Phase IIb

Ziarco Group Ltd. (Canterbury, U.K.) said ZPL-389 missed the primary endpoint of pruritus as measured on a numerical rating scale vs. placebo in a 98-patient Phase IIa study to treat moderate to severe atopic dermatitis....
BioCentury | May 16, 2016
Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
BC Week In Review | Feb 8, 2016
Clinical News

ZPL-389: Phase IIa started

Ziarco began a double-blind, placebo-controlled, international Phase IIa trial to evaluate 30 mg oral ZPL-389 once daily for 12 weeks in about 120 patients with moderate to severe psoriasis. Ziarco has exclusive, worldwide rights to...
BC Week In Review | Jul 13, 2015
Clinical News

ZPL-398: Phase IIa started

Ziarco began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 30 mg ZPL-398 once daily for 8 weeks in 90 patients with moderate to severe atopic dermatitis. Ziarco Group Ltd. , Canterbury, U.K.   Product:...
Items per page:
1 - 10 of 21